Red X iconGreen tick iconYellow tick icon

Murray Barclay (2018)Clinical Pharmacologist | Gastroenterologist

MD FRACP

Email murray.barclay@cdhb.health.nz

Professor Murray Barclay is a clinical pharmacologist, gastroenterologist, and clinical professor with the University of Otago, Christchurch. His research interests include inflammatory bowel disease genetics and pharmacogenetics, optimising medicines in gastroenterology and rheumatology, immune modulating drugs, and drug concentration monitoring.

He developed Interactive Clinical Pharmacology (www.icp.org.nz) with graphical web-based modules for teaching clinical pharmacology.

Publications

Keating, P. E., Hock, B. D., Chin, P. K. L., O'Donnell, J. L., & Barclay, M. L. (2024). Evaluation of the homogenous mobility shift assay for infliximab and adalimumab anti-drug antibody detection in the clinical laboratory. Therapeutic Drug Monitoring. Advance online publication. doi: 10.1097/ftd.0000000000001200 Journal - Research Article

Alsoud, D., Moes, D. J. A. R., Wang, Z., Soenen, R., Layegh, Z., Barclay, M., … Dreesen, E. (2024). Best practice for therapeutic drug monitoring of infliximab: Position statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring. Advance online publication. doi: 10.1097/ftd.0000000000001204 Journal - Research Other

Stamp, L. K., Keating, P., Frampton, C., Barclay, M. L., Fanning, N., Millier, M., Hessian, P. A., & O'Donnell, J. L. (2024). Relationship between adalimumab concentrations, anti-drug antibodies and disease activity in rheumatoid arthritis: A cross-sectional observational study. Journal of Rheumatology, 51(3), 242-249. doi: 10.3899/jrheum.2023-0706 Journal - Research Article

Stamp, L. K., Horsley, C., Te Karu, L., Dalbeth, N., & Barclay, M. (2023). Colchicine: The good, the bad, the ugly, and how to minimise the risks. Rheumatology, kead625. Advance online publication. doi: 10.1093/rheumatology/kead625 Journal - Research Article

Barclay, M. L., Keating, P. E., Hock, B. D., Chin, P. K. L., & O'Donnell, J. L. (2023). Infliximab or adalimumab antidrug-antibody complex size has more clinical value than concentration. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting: Transformational Pharmacology and Toxicology. 235. Retrieved from https://www.asceptasm.com Conference Contribution - Published proceedings: Abstract

Back to top